Trypanosoma cruzi: Treatment with the iron chelator desferrioxamine reduces parasitemia and mortality in experimentally infected mice

Experimental Parasitology

Volumn 117, Issue 1, 2007, Pages 43-50

  Arantes, Jerusa Marilda ^a   Pedrosa, Maria Lúcia ^a   Martins, Helen Rodrigues ^a   Veloso, Vanja Maria ^a   de Lana, Marta ^a   Bahia, Maria Terezinha ^a   Tafuri, Washington Luiz ^a   Carneiro, Cláudia Martins ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

analysis of variance; ANOVA; d.p.i.; day post infection; deoxyribonucleic acid; desferrioxamine; DFO; DFO treated non infected control; DNA; EDTA; ELISA; enzyme linked immunosorbent assay; ethylenediamine tetraacetic acid; i.p.; infected with T. cruzi but not treated with DFO; INT; intraperitoneal; Iron chelator; IT; LIT; live infusion tryptose medium; Mice; NINT; NIT; non treated non infected control; PCR; polymerase chain reaction; treatment groups infected with T. cruzi and treated with DFO; Trypanosoma cruzi

Indexed keywords

DEFEROXAMINE; IRON; IRON CHELATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; INFECTION; IRON BLOOD LEVEL; LIVER; MALE; MORTALITY; MOUSE; NONHUMAN; PARASITEMIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; DEFEROXAMINE; HEMOGLOBINS; IRON; LIVER; MALE; MICE; PARASITEMIA; SIDEROPHORES; TRYPANOSOMA CRUZI; VIRULENCE;

ANIMALIA; MUS; TRYPANOSOMA CRUZI;

EID: 34547133481     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2007.03.006     Document Type: Article

References (54)

1. Andrade S.G., Freitas L.A., Peyrol S., Pimentel A.R., and Sadigursky M. Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive serology in parasitologically cured mice. Bulletin of the World Health Organization 69 (1991) 191-197
2. Andrade S.G., Stocker-Guerret S., Pimentel A.S., and Grimaud J.A. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi under specific chemotherapy. Memórias do Instituto Oswaldo Cruz 86 (1991) 187-200
3. Association of Official Analytical Chemists, 1980. Official methods of analysis of the AOAC, third ed. AOAC, Washington.
4. Ávila H.A., Sigman D.S., Cohen L.M., Millikan R.C., and Simpson L. Polymerase chain reaction amplification of Trypanosoma cruzi kinetoplast minicircle DNA isolated from whole blood lysates: diagnosis of chronic Chagas disease. Molecular and Biochemical Parasitology 48 (1991) 211-222
5. Blakley B.R., and Hamilton D.L. The effect of iron deficiency on the immune response in mice. Drug Nutrient Interactions 5 (1988) 249-255
6. Bothwell H., Charlton R.W., Cook J.D., and Finch C.H. Iron Metabolism in Man (1979), Blackwell, Oxford pp. 284-306
7. Breidbach T., Scory S., Krauth-Siegel R.L., and Steverding D. Growth inhibition of bloodstream forms of Trypanosoma brucei by iron chelator deferoxamine. International Journal of Parasitology 32 (2002) 473-479
8. Brener Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Revista do Instituto de Medicina Tropical de São Paulo 4 (1962) 389-396
9. Brittenham G.M. Iron chelating agents. Current Therapy in Hematology and Oncology 3 (1988) 149-153
10. Camargo E.P. Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosomes in liquid media. Revista do Instituto de Medicina Tropical de São Paulo 12 (1964) 93-100
11. Canadian Council on Animal Care, 1980. Guide to the care and use of experimental animals. CCAC, Ottawa.
12. Canadian Council on Animal Care, 1984. Guide to the care and use of experimental animals. CCAC, Ottawa.
13. Cardoso J.E., and Brener Z. Hematological changes in mice experimentally infected with Trypanosoma cruzi. Memórias do Instituto Oswaldo Cruz 75 (1980) 97-104
14. Carotenuto P., Pontesilli O., Cambier J.C., and Hayward A.R. Desferoxamine blocks IL-2 receptor expression on human T lymphocytes. Journal of Immunology 136 (1986) 2342-2347
15. Cinatl Jr. J., Cinatl J., Rabenau H., Gumbel H.O., Kornhuber B., and Doerr H.W. In vitro inhibition of human cytomegalovirus replication by desferrioxamine. Antiviral Research 25 (1994) 73-77
16. Cinatl Jr. J., Cinatl J., Weber B., Rabenau H., Gumbel H.O., Chenot J.F., Scholz M., Encke A., and Doerr H.W. In vitro inhibition of human cytomegalovirus replication in human foreskin fibroblasts and endothelial cells by ascorbic acid 2-phosphate. Antiviral Research 27 (1995) 405-418
17. Crichton R.R., and Ward R.J. Structure and molecular biology of iron binding-proteins and the regulation of free iron pools. In: Lauffer R.B. (Ed). Iron and Human Diseases (1992), CRC Press, Boca Raton 23-75
18. Dallman P.R. Biochemical basis for the manifestations of iron deficiency. Annual Review in Nutrition 6 (1986) 13-40
19. Dhur A., Galan P., and Hercberg S. Iron status, immune capacity and resistance to infections. Comparative Biochemistry and Physiology 94 (1989) 11-19
20. DonFrancesco A., Deb G., De Sio L., Cozza R., and Castellano A. Role of desferrioxamine in tumor therapy. Acta Haematologica 95 (1996) 66-69
21. Esievo K.A., Saror D.I., Ilemobade A.A., and Hallaway M.H. Variation in erythrocyte and free sialic acid serum concentrations during experimental Trypanosoma vivax infection in cattle. Research in Veterinary Science 32 (1982) 1-15
22. Filardi L.S., and Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Transactions of the Royal Society of Tropical Medicine and Hygiene 81 (1987) 755-759
23. Galan P., Davila M., Mekki N., and Hereberg S. Iron deficiency, inflammatory processes and humoral immunity in children. International Journal of Vitamin and Nutrition Research 58 (1988) 225-230
24. Gomes M.L., Macedo A.M., Vago A.R., Pena S.D., Galvão L.M., and Chiari E. Trypanosoma cruzi: optimization of polymerase chain reaction for detection in human blood. Experimental Parasitology 88 (1998) 28-33
25. Gordeuk K., Thuma P., Brittenham G., McLaren C., Parry D., Backenstose A., Biemba G., Msiska R., Holmes L., McKinley E., Vargas L., Gilkeson R., and Polera A.A. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. The New England Journal of Medicine 327 (1992) 1473-1477
26. Hann H.W.L., Stahlhut M.W., Rubin R., and Maddrey W.C. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 70 (1992) 2051-2056
27. In: Henry R.J., Winkelman J.W., and Cannon D.C. (Eds). Clinical chemistry-principles and techniques. second ed. (1974), Harper & Row, New York
28. Hershko C., and Peto T.E.A. Deferroxamine inhibition of malaria is independent of host iron status. Journal of Experimental Medicine 168 (1988) 375-387
29. Igbokwe I.O., and Anosa V.O. Response to anaemia in experimental Trypanosoma vivax infection of sheep. Journal of Comparative Pathology 100 (1989) 111-118
30. Kent S., Weinberg E.D., and Stuart-MacAdam P. Dietary and prophylactic iron supplements: helpful and harmful. Human Nature 1 (1990) 55-81
31. Lalonde R.G., and Holbein B.E. Role of iron in Trypanosoma cruzi infection of mice. Journal of Clinical Investigation 23 (1984) 470-476
32. Letendre E.D. The importance of iron in the pathogenesis of infection and neoplasia. Trends in Biochemical Sciences 12 (1985) 166-168
33. Lima M.F., and Villalta F. Trypanosoma cruzi trypomastigote clones differentially express a parasite adhesion molecule. Molecular and Biochemical Parasitology 33 (1989) 159-170
34. Loo V.G., and Lalonde R.G. Role of iron in intracellular growth of Trypanosoma cruzi. Infection and Immunity 45 (1984) 726-730
35. Mabeza G.F., Biemba G., and Gordeuk V.R. Clinical studies of iron chelators in malaria. Acta Haematologica 95 (1996) 78-86
36. Mahmoud M.S. Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice. Journal of the Egyptian Society of Parasitology 29 (1999) 791-803
37. Marcondes M.C.G., Borelli P., Yoshida N., and Russo M. Acute Trypanosoma cruzi infection is associated with anemia, thrombocytopenia, leukopenia, and bone marrow hypoplasia: reversal by nifurtimox treatment. Microbes and Infection 2 (2000) 347-352
38. Martelius T., Scholz M., Krogerus L., Hockerstedt K., Loginov R., Bruggeman C., Cinatl Jr. J., Doerr H.W., and Lautenschlager I. Antiviral and immunomodulatory effects of desferrioxamine in cytomegalovirus-infected rat liver allografts with rejection. Transplantation 68 (1999) 1753-1761
39. Miyamoto C.T., Gomes M.L., Marangon A.V., Araujo S.M., Bahia M.T., Lana M., and Toledo M.J. Trypanosoma cruzi: sensitivity of the polymerase chain reaction for detecting the parasite in the blood of mice infected with different clonal genotypes. Experimental Parasitology 112 (2006) 198-201
40. Pedrosa M.L., Silva M.E., Silva M.E., Silva M.E.C., Nicoli J.R., and Vieira E.C. The effect of iron deficiency and iron overload on the evolution of Chagas' disease produced by three strains of Trypanosoma cruzi in CFW mice. Comparative Biochemistry and Physiology 97 (1990) 235-243
41. Pedrosa M.L., Nicoli J.R., Silva M.E., Silva M.E., Silva M.E.C., Vieira L.Q., Bambirra E.A., and Vieira E.C. The effect of iron nutritional status on Trypanosoma cruzi infection in germfree and conventional mice. Comparative Biochemistry and Physiology 106 (1993) 813-821
42. Richardson D.R. Iron chelators as effective anti-proliferative agents. Canadian Journal of Physiology and Pharmacology 75 (1997) 1164-1180
43. Ruiz R.C., Fernandes M., and Irulegui I. Observation of marked thrombcytopenia during the course of acute experimental Chagas' disease. Memórias do Instituto Oswaldo Cruz 84 (1989) 26
44. Santos F.R., Pena S.D.J., and Epplen J.T. Genetic and population study of a Y-linked tetranucleotide repeat DNA polymorphism with a simple non-isotopic technique. Human Genetics 90 (1993) 655-656
45. Shadid M., Buonocore G., Groenendaal F., Moison R., Ferrali M., Berger H.M., and Van Bel F. Effect of deferoxamine and allopurinol on non-protein-bound iron concentrations in plasma and cortical brain tissue of newborn lambs following hypoxia-ischemia. Neuroscience Letters 248 (1998) 5-8
46. Silva L.H.P., and Nussenzweig V. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. Folia Clinica et Biologica 20 (1953) 191-203
47. Tanjii K., Imaizumi T., Matsumiya T., Itaya H., Fujimoto K., Cui X.F., Toki T., Ito E., Yoshida H., Wakabayashi K., and Satoh K. Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line. Biochemistry Biophysics Acta 1530 (2001) 227-235
48. Traore O., Carnevale P., Kaptue-Noche L., Bede J., Desfontaine M., Elion J., Labie D., and Nagel R.L. Preliminary reports in the use of desferrioxamine in the treatment of Plasmodium falciparum malaria. American Journal of Hematology 37 (1991) 206-208
49. Voller A., Bidwell D.E., and Bartlett A. Enzyme immunoassays in diagnostic medicine. Theory and practice. Bulletin of the World Heath Organization 53 (1976) 55-65
50. Wang F., Elliot R.L., and Head J.F. Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762 NF rat mammary adenocarcinoma. Anticancer Reserach 19 (1999) 445-450
51. Weinberg E.D. Iron withholding: a defence against infection and neoplasia. Physiological Reviews 64 (1984) 65-102
52. Weinberg G.A. Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrobial Agents and Chemotherapy 38 (1994) 997-1003
53. Wincker P., Britto C., Pereira J.B., Cardoso M.A., Oelemann W., and Morel C.M. Use of a simplified polymerase chain reaction procedure to detect Trypanosoma cruzi in blood samples from chronic chagasic patients in a rural endemic area. American Journal of Tropical Medicine and Hygiene 51 (1994) 771-777
54. Wolfe L., Leitzel K., Witkoski E., Bartholomew M., and Lipton A. Desferrioxamine prolongs survival of mice with LI210 lymphocytic leukaemia. Proceedings of the American Association for Cancer Research 29 (1988) 2053